Advertisement
UK markets close in 6 hours 6 minutes
  • FTSE 100

    7,964.28
    +32.30 (+0.41%)
     
  • FTSE 250

    19,816.97
    +6.31 (+0.03%)
     
  • AIM

    742.00
    -0.11 (-0.01%)
     
  • GBP/EUR

    1.1691
    +0.0022 (+0.19%)
     
  • GBP/USD

    1.2609
    -0.0029 (-0.23%)
     
  • Bitcoin GBP

    55,869.79
    +306.07 (+0.55%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,248.49
    +44.91 (+0.86%)
     
  • DOW

    39,760.08
    +477.75 (+1.22%)
     
  • CRUDE OIL

    81.97
    +0.62 (+0.76%)
     
  • GOLD FUTURES

    2,218.90
    +6.20 (+0.28%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,501.34
    +24.25 (+0.13%)
     
  • CAC 40

    8,253.59
    +48.78 (+0.59%)
     

BUZZ-Cancer drugs: Roche impresses in immunotherapy race

** Impressive results from Roche, following release of scientific summaries, or abstracts, ahead of big ASCO oncology conference in Chicago later this month

** Strong lung cancer data for anti-PD-L1 drug MPDL3280A support Roche's diagnostic-led approach and should enable company to file for accelerated U.S. approval in second half of 2015, Deutsche Bank (Xetra: 514000 - news) analysts say

** AstraZeneca (NYSE: AZN - news) data on PD-L1 drug MEDI4736 and tremelimumab combination in lung cancer looks "solid" and remains promising, according to Jefferies

** Bristol-Myers Squibb's leading position in immuno-oncology increasingly challenged by other contenders including Merck (Other OTC: MKGAF - news) , Roche, AstraZeneca and Pfizer (NYSE: PFE - news) , says Barclays (LSE: BARC.L - news)

ADVERTISEMENT

** Key late-breaking presentations not included in initial abstracts release, pointing to more jockeying for position at May 29-June 2 ASCO scientific sessions

** AstraZeneca shares up 0.8 percent; Roche untraded in Zurich due to holiday (RM (LSE: RM.L - news) : ben.hirschler.thomsonreuters.com@reuters.net)